Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
HOME > BUSINESS
BUSINESS
- Toho Holdings Names Hiroyuki Kono as Next Chairman
April 30, 2015
- Daiichi Sankyo Cuts FY2014 Forecasts on Write-Off Loss Tied to Zelboraf
April 30, 2015
- Boehringer Japan Pharma Sales Grow 3 Times Faster than Market in 2014
April 30, 2015
- Eliquis Shows Lower Incidence of Adverse Events Including Major Bleeding in PIII Study in Patients with Acute VTE
April 28, 2015
- Lixiana Recommended for European Approval by CHMP: Daiichi Sankyo
April 28, 2015
- Sanofi Files Primaquine for Vivax Malaria, Ovale Malaria in Japan
April 28, 2015
- Novartis Seeks Japan Approval for 2 Malignant Melanoma Drugs Transferred from GSK
April 28, 2015
- Eisai, Nihon Medi-Physics Tie Up for Diagnosis, Treatment of Dementia with Lewy Bodies
April 28, 2015
- Opdivo Gains Positive CHMP Opinion for Advanced Melanoma
April 27, 2015
- Takeda’s Shonan Lab Collaborative Research Initiative Forging Ahead
April 27, 2015
- Janssen Files Risperdal for Irritability Associated with Autistic Disorder in Children
April 27, 2015
- Eisai Launches 2 Anticancer Agents in Mexico
April 27, 2015
- Bayer Seeks Japan Approval of Prostate Cancer Drug Radium-223 Dichloride
April 27, 2015
- Sumitomo Dainippon Faces Dim Prospects for Lurasidone Filing in Japan
April 27, 2015
- Astellas Sees 59% Rise in FY2014 Operating Profit
April 24, 2015
- Strategia Therapeutics Starts PI/IIa Study of Anticancer Agent Licensed from Eisai in US
April 24, 2015
- Sales Rep Survey – Part 3: Chugai, Takeda Raise Base Salaries, Reflecting “Social Trend”
April 24, 2015
- Astellas Links Up with US Biotech Potenza on Immuno-Oncology
April 23, 2015
- Shionogi Ups FY2014 Earnings Outlook on ViiV Dividends
April 23, 2015
- Ono Seeks Lung Cancer Indication for Opdivo in Japan
April 23, 2015
ページ
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…